Allarity Therapeutics, Inc. — Form 8-K
Filed July 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
On June 30, 2026, the USPTO granted Allarity's key U.S. patent covering its stenoparib-specific Drug Response Predictor (DRP) companion diagnostic, with patent protection extending to April 2042. The patent covers methods for predicting clinical benefit from stenoparib based on gene-expression profiles and selecting patients most likely to benefit from treatment. Allarity has also secured patent protection in Europe and Australia through 2039.
Why this rating
Patent grant provides 16-year IP protection for core asset; meaningful for clinical-stage biotech but execution risk and regulatory approval remain substantial unknowns.
Extracted items
- 5.07 shareholder vote
- 8.01 other event
- 9.01 exhibits
View original filing on SEC.gov ↗
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.